Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, has welcomed final recommendations from Australia's Therapeutic Goods Administration (TGA) regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond hospital environments, and supports scaling of psychedelic-assisted therapy across Australia, where authorized psychiatrists can prescribe Optimi's GMP-compliant MDMA for PTSD and psilocybin for treatment-resistant depression.
The company said the revised framework could accelerate adoption of psychedelic-assisted therapy by increasing workforce capacity, particularly in rural and regional areas, while expanding reimbursement opportunities across both public and private payers. This move is expected to address key barriers to access, including limited provider availability and restrictive treatment settings, which have historically slowed the integration of these therapies into mainstream healthcare.
Optimi also noted that no serious adverse events have been reported under Australia's regulated commercial psychedelic treatment program since December 2025, supporting continued expansion of what the company describes as the world's most advanced commercial market for prescribed psilocybin and MDMA therapies. The safety record reinforces the potential for broader adoption and could encourage other countries to follow Australia's lead in establishing regulated frameworks.
For the psychedelic industry, Australia's progressive regulatory environment serves as a model for other jurisdictions considering similar reforms. The TGA's updates may streamline the path for companies like Optimi to scale their operations and enter new markets. As reimbursement opportunities expand, healthcare providers could see increased demand for psychedelic-assisted therapies, potentially driving revenue growth for pharmaceutical manufacturers and treatment centers.
Optimi Health Corp. is a Canadian GMP-certified pharmaceutical manufacturer specializing in the regulated production and international export of MDMA and psilocybin for prescription-based mental health therapies. The full press release is available at https://nnw.fm/yYW7j. For more information about Optimi, visit https://www.optimi.net/.
Forward-looking statements in this article involve risks and uncertainties as detailed in the company's filings with the SEC. Readers are referred to the risk factors in Optimi's most recent Annual Report on Form 10-K and subsequent filings. The company undertakes no duty to update this information unless required by law.
